SCHEMBL62746

SCHEMBL62746

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCCc2cccc(Cl)c2)c(O)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.39
HIF1A Q16665 1/20 0.36
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
BCL2 P10415 1/20 0.35
BCL2L1 Q07817 1/20 0.35
MCL1 Q07820 1/20 0.35
LMNA P02545 1/20 0.35
CYP2C9 P11712 1/20 0.35
TAAR1 Q96RJ0 2/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
GLA P06280 1/20 0.35
AKT3 Q9Y243 1/20 0.35
HTT P42858 1/20 0.35
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63541 0.93 CYP2C9 (0.40) NPC1MEN1KMT2ALMNACYP2C9
SCHEMBL63901 0.91 CYP2C9 (0.38) ABCB1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL64254 0.91 CYP2C9 (0.38) ABCB1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL63903 0.88 CYP2C9 (0.39) NPC1RAB9ASMN1; SMN2GAACYP2C9
SCHEMBL63498 0.87 MAPT (0.36) HIF1ASMN1; SMN2MEN1GAAKMT2A
SCHEMBL63505 0.86 L3MBTL1 (0.39) NPC1RAB9ASMN1; SMN2CYP2C9ALDH1A1
SCHEMBL64541 0.86 CYP2C9 (0.46) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL64292 0.86 CYP2C9 (0.41) CYP2C9
SCHEMBL52496 0.86 LIPG (0.43)
SCHEMBL63523 0.85 KDM4E (0.40) SMN1; SMN2MEN1GAAKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ABCB1 76/4885HIF1A 3376/4885NPC1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.